Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friedegund Meier

Showing results (71-80 of 234) with videos related to

Pageof 24
Sort By:
Pigment Cell & Melanoma Research|June 27, 2015
PTEN regulates IGF-1R-mediated therapy resistance in melanomaJun Wang, Tobias Sinnberg, Heike Niessner, et al.
International Journal of Molecular Sciences|July 29, 2023
Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and TreatmentJulian Steininger, Frank Friedrich Gellrich, Kay Engellandt, et al.
Cell Death and Differentiation|February 22, 2020
Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonismVesna Vetma, Cristiano Guttà, Nathalie Peters, et al.
Experimental Dermatology|April 20, 2017
Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1Heike Niessner, Corinna Kosnopfel, Tobias Sinnberg, et al.
Neuro-Oncology Advances|December 11, 2020
An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER studyTeresa Amaral, Heike Niessner, Tobias Sinnberg, et al.
Plos One|January 26, 2012
Prognosis of sentinel node staged patients with primary cutaneous melanomaOtmar Elsaesser, Ulrike Leiter, Petra G Buettner, et al.
International Journal of Cancer|February 11, 2012
Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cellsSarah Schott, Heike Niessner, Tobias Sinnberg, et al.
Journal of the American Academy of Dermatology|April 25, 2009
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patientsFriedegund Meier, Emmanuella Guenova, Stephan Clasen, et al.
Journal of Cell Science|September 2, 2004
The RacGEF Tiam1 inhibits migration and invasion of metastatic melanoma via a novel adhesive mechanismKatharina Uhlenbrock, Alexander Eberth, Ulrike Herbrand, et al.
Plos One|May 3, 2013
Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosisBenjamin Weide, Christine Faller, Petra Büttner, et al.
Pageof 24

Showing results (71-80 of 234) with videos related to

Sort By:
Pageof 24
Pigment Cell & Melanoma Research|June 27, 2015
PTEN regulates IGF-1R-mediated therapy resistance in melanomaJun Wang, Tobias Sinnberg, Heike Niessner, et al.
International Journal of Molecular Sciences|July 29, 2023
Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and TreatmentJulian Steininger, Frank Friedrich Gellrich, Kay Engellandt, et al.
Cell Death and Differentiation|February 22, 2020
Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonismVesna Vetma, Cristiano Guttà, Nathalie Peters, et al.
Experimental Dermatology|April 20, 2017
Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1Heike Niessner, Corinna Kosnopfel, Tobias Sinnberg, et al.
Neuro-Oncology Advances|December 11, 2020
An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER studyTeresa Amaral, Heike Niessner, Tobias Sinnberg, et al.
Plos One|January 26, 2012
Prognosis of sentinel node staged patients with primary cutaneous melanomaOtmar Elsaesser, Ulrike Leiter, Petra G Buettner, et al.
International Journal of Cancer|February 11, 2012
Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cellsSarah Schott, Heike Niessner, Tobias Sinnberg, et al.
Journal of the American Academy of Dermatology|April 25, 2009
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patientsFriedegund Meier, Emmanuella Guenova, Stephan Clasen, et al.
Journal of Cell Science|September 2, 2004
The RacGEF Tiam1 inhibits migration and invasion of metastatic melanoma via a novel adhesive mechanismKatharina Uhlenbrock, Alexander Eberth, Ulrike Herbrand, et al.
Plos One|May 3, 2013
Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosisBenjamin Weide, Christine Faller, Petra Büttner, et al.
Pageof 24